<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004245</url>
  </required_header>
  <id_info>
    <org_study_id>99-057</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-99057</secondary_id>
    <secondary_id>NCI-G99-1661</secondary_id>
    <nct_id>NCT00004245</nct_id>
  </id_info>
  <brief_title>Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase I Study of Salicylate for Adult Patients With Advanced Myelodysplastic Disorders or Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of sodium salicylate in treating patients&#xD;
      who have advanced myelodysplastic syndrome , acute myelogenous leukemia or chronic&#xD;
      lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the safety, toxicity, and pharmacokinetics of sodium salicylate in patients&#xD;
           with advanced myelodysplastic syndrome; newly diagnosed, relapsed, or refractory acute&#xD;
           myelogenous leukemia; or relapsed or refractory chronic lymphocytic leukemia.&#xD;
&#xD;
        -  Define biologic characteristics that influence the likelihood of a clinical response to&#xD;
           this drug in this patient population.&#xD;
&#xD;
      OUTLINE: Patients receive oral sodium salicylate twice a day. Intrapatient dose escalation or&#xD;
      de-escalation is permitted. Treatment continues for up to 6 weeks in the absence of&#xD;
      unacceptable toxicity or disease progression. Responding patients may continue to receive&#xD;
      sodium salicylate beyond the 6-week period.&#xD;
&#xD;
      Patients with acute myelogenous leukemia are followed until the end of therapy. Patients with&#xD;
      myelodysplastic syndrome are followed until death or progression to leukemia.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium salicylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Relapsed or refractory acute myelogenous leukemia OR&#xD;
&#xD;
          -  Elderly patients with newly diagnosed acute myelogenous leukemia not eligible for&#xD;
             standard therapy OR&#xD;
&#xD;
          -  &quot;High-risk&quot; myelodysplastic syndrome, including:&#xD;
&#xD;
               -  Refractory anemia with excess blasts&#xD;
&#xD;
               -  Refractory anemia with excess blasts in transformation&#xD;
&#xD;
               -  Chronic myelomonocytic leukemia OR&#xD;
&#xD;
          -  Relapsed or refractory chronic lymphocytic leukemia&#xD;
&#xD;
          -  Not eligible for transplant protocols at MSKCC or refuses transplant&#xD;
&#xD;
          -  Not eligible for a higher priority protocol (e.g., bone marrow transplantation)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 25,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Transaminase levels less than 3 times upper limit of normal&#xD;
&#xD;
          -  PT no greater than 14 seconds&#xD;
&#xD;
          -  PTT no greater than 34.6 seconds&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No history of abnormal bleeding or unexplained bleeding disorders&#xD;
&#xD;
          -  No history of peptic ulcer disease&#xD;
&#xD;
          -  No salicylate allergy&#xD;
&#xD;
          -  No other concurrent active malignancy&#xD;
&#xD;
          -  No other concurrent illness that would preclude study assessment to a significant&#xD;
             degree&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Klimek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Klimek VM, Dolezal EK, Smith L, Soff G, Nimer SD. Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia. Leuk Res. 2012 May;36(5):570-4. doi: 10.1016/j.leukres.2011.10.023. Epub 2011 Dec 9.</citation>
    <PMID>22154022</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
    <mesh_term>Salicylsalicylic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

